Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer

Published:2017-04-30 Issue:5B Volume:120 Page:E80-E86
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Howard Lauren E.¹²,Moreira Daniel M.³,De Hoedt Amanda²,Aronson William J.⁴⁵,Kane Christopher J.⁶,Amling Christopher L.⁷,Cooperberg Matthew R.⁸,Terris Martha K.⁹¹⁰,Freedland Stephen J.²¹¹

Affiliation:

1. Department of Biostatistics and Bioinformatics; Duke University School of Medicine; Durham NC USA

2. Division of Urology; Veterans Affairs Medical Center; Durham NC USA

3. Department of Urology; University of Illinois at Chicago; Chicago IL USA

4. Department of Urology; UCLA School of Medicine; Los Angeles CA USA

5. Urology Section; Department of Surgery; Veterans Affairs Greater Los Angeles Healthcare System; Los Angeles CA USA

6. Urology Department; University of California San Diego Health System; San Diego CA USA

7. Division of Urology; Department of Surgery; Oregon Health and Science University; Portland OR USA

8. Department of Urology; UCSF Helen Diller Family Comprehensive Cancer Center; San Francisco CA USA

9. Section of Urology; Veterans Affairs Medical Center; Augusta GA USA

10. Section of Urology; Medical College of Georgia; Augusta GA USA

11. Division of Urology; Department of Surgery; Samuel Oschin Comprehensive Cancer Institute; Cedars-Sinai Medical Center; Los Angeles CA USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13856/fullpdf

Reference24 articles.

1. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer;Moreira;Prostate Cancer Prostatic Dis,2015

2. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy;Freedland;JAMA,2005

3. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer;Klotz;J Clin Oncol,2010

4. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy;D'Amico;J Natl Cancer Inst,2003

5. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer;Smith;J Clin Oncol,2005

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors for non‑metastatic castration‑resistant prostate cancer treated with androgen receptor signaling inhibitors;Molecular and Clinical Oncology;2024-08-08

2. Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study;Advances in Radiation Oncology;2024-08

3. Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy;Cancers;2024-07-26

4. Management of advanced prostate cancer in the Asia‐Pacific region: Summary of the Asia‐Pacific Advanced Prostate Cancer Consensus Conference 2023;Asia-Pacific Journal of Clinical Oncology;2024-04-16

5. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-02